clinical trial · NCT06274788
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
Fresenius Kabi·—·recruiting·n = 40
Parenteral Nutrition Associated Liver Disease (PNALD)Essential Fatty Acid DeficiencyMalnutritionPediatric ALLOmegaven® (fish oil triglycerides) Injectable Emulsion
brief summary
This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population
started
Dec 15, 2024
primary completion
Mar 1, 2026
completion
Mar 1, 2027
last updated
Sep 5, 2025
official title
Title: A Single-arm, Open-label, Prospective, Multicenter Safety Study to Evaluate the Occurrence of Essential Fatty Acid Deficiency (EFAD) in Pediatric Patients With Parenteral Nutrition-associated Cholestasis (PNAC) Who Require More Than Eight Weeks of Omegaven Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol